NCT03932409 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03932409
Title	Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer (FIERCE)
Acronym	FIERCE
Recruitment	Active, not recruiting
Gender	female
Phase	Phase I
Variant Requirements	No
Sponsors	University of Oklahoma
Indications	endometrial carcinoma
Therapies	Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
LSU Health New Orleans		New Orleans	Louisiana	70112	United States	Details
Stephenson Cancer Center		Oklahoma City	Oklahoma	73104	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03932409Clinical Trial Detail